AIH, autoimmune hepatitis; ALT, alanine aminotransferase; AMA, anti-mitochondrial antibodies; ANA, anti-nuclear antibodies; AP, alkaline phosphatase; APS, anti-phospholipid-antibody syndrome; AZA, azathioprine; Autoimmune hepatitis; Autoimmune liver disease; BDN, budesonide; Belimumab; CI, calcineurin inhibitor; CyA, cyclosporine A; INR, international normalized ratio; IgG, immunoglobulin G; IgM, immunoglobulin M; LC 1, liver cytosol 1 antibodies; LKM-1, liver-kidney-microsomal antibodies; MMF, mycophenolate mofetil; MRCP, magnetic resonance cholangiopancreatography; NA, not applicable; NRH, nodular regenerative hyperplasia; PBC, primary biliary cholangitis; PDN, prednisolone; PLA2R, anti-phospholipase 2 receptor antibody; PSC, primary sclerosing cholangitis; Primary biliary cholangitis; RF, rheumatoid factor; SLA, soluble liver antigen antibodies; SLE, systemic lupus erythematosus; SMA, smooth-muscle cell antibodies; SS-A, SS-A (Ro) antibodies; SS-B, SS-B (La) antibodies; Sjögren's disease; TNFi, tumor necrosis factor inhibitor; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; disease-modifying anti-rheumatic drugs, DMARDs